Sugi Predict

Sugi Predict / Compounds / SCHEMBL187283

SCHEMBL187283

SCHEMBL187283

CC(C)(C)c1ccc(NC(=O)c2cccnc2Nc2ccc3cn[nH]c3c2)cc1CCCC1CCCNC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 1/20 0.49
▸ HPGD P15428 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ SYK P43405 3/20 0.38
▸ BTK Q06187 2/20 0.38
▸ TRPV1 Q8NER1 2/20 0.37
▸ MET P08581 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ FLT1 P17948 1/20 0.35
▸ CFTR P13569 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ACP1 P24666 1/20 0.35
▸ CLK2 P49760 1/20 0.34
▸ PRKX P51817 1/20 0.34
▸ CAMK2D Q13557 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3890617 0.96 KDR (0.51) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL13867871 0.83 KDR (0.53) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL13867869 0.83 KDR (0.53) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL3891782 0.82 KDR (0.49) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL447675 0.81 KDR (0.51) KDRFLT1
SCHEMBL3898254 0.80 KDR (0.51) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL3891634 0.79 KDR (0.55) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL3890853 0.78 KDR (0.55) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL3892509 0.78 KDR (0.54) KDRHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL13867931 0.78 KDR (0.54) KDRHPGDNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060216288-A1 Combinations for the treatment of cancer AMGEN INC (US) 2006-09-28 — — US claimed
US-7105682-B2 Substituted amine derivatives and methods of use AMGEN INC. (US) 2006-09-12 — — US claimed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 — — US claimed
EP-3170824-B1 A 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVE AS C-MET INHIBITOR AMGEN INC (US) 2020-07-01 — — EP disclosed
EP-3330292-A1 HUMAN C-FMS ANTIGEN BINDING PROTEINS Amgen, Inc (US) 2018-06-06 — — EP disclosed
US-9988457-B2 Human C-FMS antigen binding proteins AMGEN INC. (US) 2018-06-05 — — US disclosed
EP-2188313-B1 HUMAN C-FMS ANTIGEN BINDING PROTEINS AMGEN INC (US) 2017-11-01 — — EP disclosed
US-20170247459-A1 COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF HOFFMANN-LA ROCHE INC. (US) 2017-08-31 — — US disclosed
US-9745288-B2 Compounds and methods for treating cancer by inhibiting the urokinase receptor INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2017-08-29 — — US disclosed
EP-2231663-B1 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS AMGEN INC (US) 2017-08-02 — — EP disclosed
EP-3170824-A1 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS Amgen, Inc (US) 2017-05-24 — — EP disclosed
US-20060018909-A1 Angiopoietin-2 specific binding agents AMGEN INC. 2006-01-26 — — US disclosed
EP-1562933-A2 SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS Amgen Inc. (US) 2005-08-17 — — EP disclosed
US-20050118643-A1 Specific binding agents to hepatocyte growth factor AMGEN INC 2005-06-02 — — US disclosed
WO-2005017107-A2 SPECIFIC BINDING AGENTS TO HEPATOCYTE GROWTH FACTOR AMGEN INC. (US) 2005-02-24 — — WO disclosed
EP-1467721-A2 SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS Amgen Inc. (US) 2004-10-20 — — EP disclosed
WO-2004007481-A2 SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS AMGEN INC. (US) 2004-01-22 — — WO disclosed
US-20030203922-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-30 — — US disclosed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 — — US disclosed
WO-2002068406-A2 SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS AMGEN INC. (US) 2002-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060216288-A1 Combinations for the treatment of cancer TP53, VHL, FOLR2 KDR 2043/4885HPGD 470/4885NPC1 593/4885
US-20030203922-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 KDR 13/4885HPGD 99/4885NPC1 782/4885
US-20030195230-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 KDR 13/4885HPGD 99/4885NPC1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.